Latest Clinical Trial Results News

Microba Life Sciences reports a 145% jump in core microbiome test volumes and is on track to achieve regional break-even by FY26, supported by strategic cost cuts and a $14.5 million capital raise.

Clarity Pharmaceuticals has responded to ASX queries clarifying the timing and materiality of its SAR-bisFAP data presentation, denying the information was price sensitive despite a notable share price rise.

Imricor Medical Systems has completed the world’s first Pulsed Field Ablation procedure under real-time MRI guidance, marking a breakthrough in cardiac ablation technology. This pre-clinical success validates their Vision-MR platform’s adaptability and sets the stage for safer, radiation-free heart treatments.

Immutep Limited’s Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma patients has exceeded its primary endpoint, showing a 51.5% median tumor hyalinization rate, more than triple the historical standard. These promising results, presented at ESMO 2025, suggest a potential breakthrough in a challenging cancer indication.

Vectus Biosystems has temporarily paused trading of its securities pending a forthcoming announcement, signaling potential material news for investors.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.